Market Cap 3.62B
Revenue (ttm) 36.13M
Net Income (ttm) -215.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -595.99%
Debt to Equity Ratio 0.00
Volume 1,303,700
Avg Vol 1,249,748
Day's Range N/A - N/A
Shares Out 69.21M
Stochastic %K 83%
Beta 1.00
Analysts Strong Sell
Price Target $90.14

Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cel...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 30 253 8800
Address:
Uppsalalaan 17, 3rd & 4th floor, Utrecht, Netherlands
Llamalamb2921
Llamalamb2921 Jul. 8 at 12:35 PM
$MRUS Shareholders here need to look at $PDSB. Market cap is $56M vs nearly $4B for Merus. PDSB is the cleanest play for the lucrative and growing HPV16+ population. Versamune technology also lends itself to other immunotherapy antigens like MUC-1 as well as excellent study results in Universal Flu vaccine hopefully going into human trials soon.
1 · Reply
JarvisFlow
JarvisFlow Jun. 26 at 10:00 AM
BMO Capital updates rating for Merus ( $MRUS ) to Outperform, target set at 91 → 96.
0 · Reply
YasirTrades
YasirTrades Jun. 20 at 12:05 AM
GLMD The risk/reward is insane. Under $2. Cash-rich. No debt. $12+ book. GLP-1 & fibrosis catalysts ahead. No fluff, just facts. $EPIX $ADIL $MRUS $MBOT $SYTA 🚨🚨🚨🚨
0 · Reply
Bionoobbb
Bionoobbb Jun. 14 at 4:11 AM
$MRUS $PDSB Merus 🔹 Target Population: Merus is conducting clinical trials targeting first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). These trials include both HPV-positive and HPV-negative patients. The main therapy is a combination of petosemtamab with Keytruda. 🔹 Current Status: • These trials require patients to be PD-1–naïve (i.e., they must not have received prior anti–PD-1 therapy). • With Keytruda now moving into perioperative use in early-stage disease, a growing portion of patients will receive Keytruda earlier in their treatment journey. • When these patients eventually experience recurrence, they will no longer be eligible for Merus trials due to prior PD-1 exposure. 🔹 Conclusion: ❌ This creates significant near- and long-term negative impact. As Keytruda use expands in early settings, Merus’s addressable patient pool continues to shrink.
1 · Reply
Bionoobbb
Bionoobbb Jun. 13 at 2:00 PM
$PDSB $MRUS @DubK FDA has approved $MRK keytruda in neoadjuvant which will reduce the patient pool for MRUS & $BCAX Smaller Patient Pool • Merck’s Keytruda just got approved for (neoadjuvant use) • Since Keytruda is now approved and proven, doctors may choose it over joining a new trial for an experimental drug. • Result: Fewer patients may join Merus’ trial, making it harder for them to prove their drug works or to sell it later.
0 · Reply
fezziwig2018
fezziwig2018 Jun. 12 at 6:33 PM
“HPV16 & HPV18 are the main high-risk types responsible for both cervical and HNSCC, with HPV16 accounting for 90% of HPV+ OPSCC” https://mdpi.com/1422-0067/23/7/3483 $PDSB targets 16-by far more/more difficult cases of head/neck ca vs $MRUS (strains of 8 pts included in last data omitted) https://www.mdpi.com/1422-0067/23/7/3483
0 · Reply
bmess
bmess Jun. 6 at 7:15 PM
$MRUS not very smart
0 · Reply
OptionsSean
OptionsSean Jun. 6 at 4:56 PM
The market tipped it's hand earlier this week in $MRUS. I'm buying this dip:
1 · Reply
Ontherag
Ontherag Jun. 6 at 2:55 PM
$MRUS Hey Bill, ask KevinHarrington what he thinks. Thanks.
0 · Reply
Llamalamb2921
Llamalamb2921 Jun. 6 at 11:03 AM
$MRUS I strongly recommend that your CEO Bill Lundberg speak with Frank at $PDSB to learn specifically about HPV16+ HNSCC. If not Frank, he can speak to other experts in the field regarding HPV16+ cancers and how they differ from other subsets of HPV+ HNSCC. Bill may need to temper his enthusiasm a bit and give some credit to the people at PDSB with their $65M market cap. He touches his heart a lot and seems to care very much for patients. Would he choose his drug trial for a loved one with an HPV16+ malignancy? Stick to HPV negative tumors Bill. There is enough room in the space for both companies to be successful.
0 · Reply
Latest News on MRUS
Merus to Present at Upcoming Investor Conferences

May 27, 2025, 8:00 AM EDT - 6 weeks ago

Merus to Present at Upcoming Investor Conferences


Merus to Present at BofA Securities 2025 Health Care Conference

May 8, 2025, 8:00 AM EDT - 2 months ago

Merus to Present at BofA Securities 2025 Health Care Conference


Merus: Riding The Bispecific Wave In Oncology

Apr 7, 2025, 4:34 AM EDT - 3 months ago

Merus: Riding The Bispecific Wave In Oncology


Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Jan 20, 2025, 5:08 AM EST - 6 months ago

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff


Merus Scores Its First FDA Approval For Lung Cancer Drug

Dec 5, 2024, 2:49 PM EST - 7 months ago

Merus Scores Its First FDA Approval For Lung Cancer Drug


Merus: Petosemtamab Set Up For December 2024 Data Presentation

Nov 5, 2024, 1:18 PM EST - 8 months ago

Merus: Petosemtamab Set Up For December 2024 Data Presentation


Merus Receives FDA extension of PDUFA for zenocutuzumab

Nov 5, 2024, 6:30 AM EST - 8 months ago

Merus Receives FDA extension of PDUFA for zenocutuzumab


Merus: Great European Oncology Developer, But Properly Valued

Aug 14, 2024, 5:13 PM EDT - 11 months ago

Merus: Great European Oncology Developer, But Properly Valued


Under-the-radar biotech bets

Apr 3, 2024, 1:47 PM EDT - 1 year ago

Under-the-radar biotech bets

CRNX SNDX XBI


Merus to Participate in Upcoming Investor Conferences

Jan 31, 2024, 8:00 AM EST - 1 year ago

Merus to Participate in Upcoming Investor Conferences


Llamalamb2921
Llamalamb2921 Jul. 8 at 12:35 PM
$MRUS Shareholders here need to look at $PDSB. Market cap is $56M vs nearly $4B for Merus. PDSB is the cleanest play for the lucrative and growing HPV16+ population. Versamune technology also lends itself to other immunotherapy antigens like MUC-1 as well as excellent study results in Universal Flu vaccine hopefully going into human trials soon.
1 · Reply
JarvisFlow
JarvisFlow Jun. 26 at 10:00 AM
BMO Capital updates rating for Merus ( $MRUS ) to Outperform, target set at 91 → 96.
0 · Reply
YasirTrades
YasirTrades Jun. 20 at 12:05 AM
GLMD The risk/reward is insane. Under $2. Cash-rich. No debt. $12+ book. GLP-1 & fibrosis catalysts ahead. No fluff, just facts. $EPIX $ADIL $MRUS $MBOT $SYTA 🚨🚨🚨🚨
0 · Reply
Bionoobbb
Bionoobbb Jun. 14 at 4:11 AM
$MRUS $PDSB Merus 🔹 Target Population: Merus is conducting clinical trials targeting first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). These trials include both HPV-positive and HPV-negative patients. The main therapy is a combination of petosemtamab with Keytruda. 🔹 Current Status: • These trials require patients to be PD-1–naïve (i.e., they must not have received prior anti–PD-1 therapy). • With Keytruda now moving into perioperative use in early-stage disease, a growing portion of patients will receive Keytruda earlier in their treatment journey. • When these patients eventually experience recurrence, they will no longer be eligible for Merus trials due to prior PD-1 exposure. 🔹 Conclusion: ❌ This creates significant near- and long-term negative impact. As Keytruda use expands in early settings, Merus’s addressable patient pool continues to shrink.
1 · Reply
Bionoobbb
Bionoobbb Jun. 13 at 2:00 PM
$PDSB $MRUS @DubK FDA has approved $MRK keytruda in neoadjuvant which will reduce the patient pool for MRUS & $BCAX Smaller Patient Pool • Merck’s Keytruda just got approved for (neoadjuvant use) • Since Keytruda is now approved and proven, doctors may choose it over joining a new trial for an experimental drug. • Result: Fewer patients may join Merus’ trial, making it harder for them to prove their drug works or to sell it later.
0 · Reply
fezziwig2018
fezziwig2018 Jun. 12 at 6:33 PM
“HPV16 & HPV18 are the main high-risk types responsible for both cervical and HNSCC, with HPV16 accounting for 90% of HPV+ OPSCC” https://mdpi.com/1422-0067/23/7/3483 $PDSB targets 16-by far more/more difficult cases of head/neck ca vs $MRUS (strains of 8 pts included in last data omitted) https://www.mdpi.com/1422-0067/23/7/3483
0 · Reply
bmess
bmess Jun. 6 at 7:15 PM
$MRUS not very smart
0 · Reply
OptionsSean
OptionsSean Jun. 6 at 4:56 PM
The market tipped it's hand earlier this week in $MRUS. I'm buying this dip:
1 · Reply
Ontherag
Ontherag Jun. 6 at 2:55 PM
$MRUS Hey Bill, ask KevinHarrington what he thinks. Thanks.
0 · Reply
Llamalamb2921
Llamalamb2921 Jun. 6 at 11:03 AM
$MRUS I strongly recommend that your CEO Bill Lundberg speak with Frank at $PDSB to learn specifically about HPV16+ HNSCC. If not Frank, he can speak to other experts in the field regarding HPV16+ cancers and how they differ from other subsets of HPV+ HNSCC. Bill may need to temper his enthusiasm a bit and give some credit to the people at PDSB with their $65M market cap. He touches his heart a lot and seems to care very much for patients. Would he choose his drug trial for a loved one with an HPV16+ malignancy? Stick to HPV negative tumors Bill. There is enough room in the space for both companies to be successful.
0 · Reply
bmess
bmess Jun. 6 at 2:48 AM
$MRUS y’all are cooked
0 · Reply
DylanGFM
DylanGFM Jun. 6 at 2:42 AM
$MRUS $MRUS public trading started years ago I know but it was a beautiful start. that kind of history with a continued gain over time alone just shows the consistency of this stock versus all the other noise
0 · Reply
Herrfranz
Herrfranz Jun. 5 at 7:32 PM
$MRUS https://youtu.be/4UBXaksMRAQ
0 · Reply
Ontherag
Ontherag Jun. 5 at 7:07 PM
$MRUS Damn, raised 300M just to rerun trials because they have the wrong patient population, frickin disaster
0 · Reply
DonCorleone77
DonCorleone77 Jun. 4 at 7:45 PM
$MRUS $MSFT $NIO $PENN $PYPL Hello Everyone, Just wanted to inform you that I have made posts TODAY with analyst information regarding the stocks below (the number of posts for each stock are in parenthesis). I will also be posting more analyst information for additional stocks later tonight and will post an update when I am done. The easiest way to find the information is via my feed located at: https://x.com/CorleoneDon77 PLEASE FEEL FREE TO RE-SHARE THIS MESSAGE IF THERE ARE ANY OF YOUR FOLLOWERS WHO YOU BELIEVE CAN BENEFIT FROM THIS INFORMATION. Here is a list of the stocks: 1) AAPL (1) 2) CEG (1) 3) CRDO (1) 4) DKNG (1) 5) DOCU (1) 6) HIMS (3) 7) LEU (1) 8) LITE (1) 9) LOW (1) 10) LYFT (1) 11) MRUS (2) 12) MSFT (1) 13) NIO (1) 14) PENN (1) 15) PYPL (1) 16) SNDX (1) 17) SNOW (1) 18) SOC (1) 19) TSLA (1) 20) WFC (4)
0 · Reply
bmess
bmess Jun. 4 at 7:17 PM
$MRUS 25-27$
0 · Reply
kshonstocks
kshonstocks Jun. 4 at 6:02 PM
$MRUS holding key offering level still, will add good close on it
0 · Reply
bmess
bmess Jun. 4 at 3:58 PM
$MRUS yeah this is a scam company that's
0 · Reply
Herrfranz
Herrfranz Jun. 4 at 2:52 PM
$MRUS added 200 shares, now 800 in total. long!
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 4 at 1:15 PM
$MRUS (-7.9% pre) Merus N.V. (MRUS) Prices 5.26M Share Offering at $57/sh https://ooc.bz/l/66879
0 · Reply
m322m
m322m Jun. 4 at 1:01 PM
$MRUS wow I can buy at 57 this is amazing 👌 thank you
0 · Reply
briefingcom
briefingcom Jun. 4 at 11:58 AM
Gapping Down: $ASAN -11.5% $CRWD -6.5% $MRUS -5.5% $ZBIO -5.4%
0 · Reply